U.S. Markets open in 31 mins

Today's Research Reports on Titan Medical, Nuvo Pharmaceuticals, CardioComm Solutions and Covalon Technologies

NEW YORK, NY / ACCESSWIRE / July 17, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

Titan Medical Inc.
https://rdinvesting.com/news/?ticker=TMD.TO

Nuvo Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=NRI.TO

CardioComm Solutions, Inc.
https://rdinvesting.com/news/?ticker=EKG.V

Covalon Technologies Ltd.
https://rdinvesting.com/news/?ticker=COV.V

Titan Medical's stock fell 13.77% Monday, to close the day at $5.51. The stock recorded a trading volume of 52,848 shares, which was above its three months average volume of 13,511 shares. In the last year, Titan Medical's shares have traded in a range of 5.40 - 612.00. The stock is currently trading 99.10% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $110.32 is below its 200-day moving average of $249.68. Shares of Titan Medical have fallen approximately 98.39 percent year-to-date.

Access RDI's Titan Medical Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TMD.TO

On Monday, shares of Nuvo Pharmaceuticals recorded a trading volume of 10,000 shares, which was below the three months average volume of 11,578 shares. The stock ended the day 1.52% lower at 2.60. The stock is currently trading 44.09% below its 52 week high with a 52 week trading range of 2.60 - 4.65. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.70 is below its 200-day moving average of $3.23. Shares of Nuvo Pharmaceuticals have fallen approximately 29.73 percent year-to-date.

Access RDI's Nuvo Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NRI.TO

CardioComm Solutions' stock jumped 20.00% Monday, to close the day at $0.06. The stock recorded a trading volume of 53,500 shares, which was below its three months average volume of 154,617 shares. In the last year, CardioComm Solutions' shares have traded in a range of 0.05 - 0.09. The share price has gained 20.00% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.05 is at its 200-day moving average of $0.05. Shares of CardioComm Solutions have gained approximately 20 percent year-to-date.

Access RDI's CardioComm Solutions, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EKG.V

On Monday, shares of Covalon Technologies recorded a trading volume of 5,381 shares, which was below the three months average volume of 24,656 shares. The stock ended the day flat at 7.99. The share price has gained 295.54% from its 52 week low with a 52 week trading range of 2.02 - 8.80. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $7.73 is greater than its 200-day moving average of $5.80. Shares of the company are trading at a Price to Earnings ratio of 199.75. Shares of Covalon Technologies have gained approximately 63.39 percent year-to-date.

Access RDI's Covalon Technologies Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=COV.V

Our Actionable Research on Titan Medical Inc. (TSX: TMD.TO) and Nuvo Pharmaceuticals Inc. (TSX: NRI.TO) and CardioComm Solutions, Inc. (TSX-V: EKG.V) and Covalon Technologies Ltd. (TSX-V: COV.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com